Connect with us

Business

UK’s Turing AI Institute bosses respond to staff anger

Published

on

UK’s Turing AI Institute bosses respond to staff anger


The heads of the UK’s national institute for artificial intelligence (AI) have told staff they accept recent months have been “challenging” for staff as the charity undergoes “substantial” change.

It comes after staff raised “serious and escalating concerns” in a whistleblowing complaint this week submitted to the Charity Commission.

They warned that the body – which receives £100m from the government – is at risk of collapse after Technology Secretary Peter Kyle instructed it to prioritise defence, and threatened to pull its funding if it did not.

In a letter seen by the BBC, Chair Dr Doug Gurr said the Turing institute would “step up at a time of national need”.

He said it had already established a new senior working group comprising government officials and Turing institute staff.

However he said defence should not be the “sole focus” and some work on healthcare and environmental issues would continue in line with the aims of both the government and private investors.

Whistleblowers have described the management’s response as “performative”.

“Just talk, no action, nothing has changed,” they said, speaking to the BBC on condition of anonymity because they fear losing their jobs for speaking out.

Dr Gurr and Chief Executive Dr Jean Innes did not respond directly to accusations by the whistleblowers about a toxic internal culture of “retaliation” and “defensiveness”.

The pair said they had not seen the letter sent from whistleblowers to the Charity Commission, which has been shared with the BBC.

“We are committed to conducting our business with honesty, integrity and transparency and believe that a culture of openness and accountability is essential,” they wrote, and linked to the Turing institute’s whistleblowing guidelines.

Founded in 2015 as the UK’s leading centre of AI research, the Turing institute, which is headquartered at the British Library in London, has been rocked by internal discontent and criticism of its research activities.

The shift to focusing on defence represents a significant pivot for the publicly funded organisation.

Both the whistleblowers and the technology secretary have said they want new leaders at the Institute – but there was no mention of any change in the management team in the letter.

A number of senior staff have left the organisation in recent months, and bosses said more people would either be made redundant or not have their contracts renewed as the restructure continues.



Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site

Published

on

Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site


The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025.

Mike Blake | Reuters

Eli Lilly on Monday said it is lowering the cash prices of single-dose vials of its blockbuster weight loss drug Zepbound on its direct-to-consumer platform, LillyDirect, building on efforts by the company and the Trump administration to make the medicine more accessible.

The announcement also comes weeks after chief rival Novo Nordisk unveiled additional discounts on the cash prices of its obesity and diabetes drugs. 

Starting Monday, cash-paying patients with a valid prescription can get the starting dose of Zepbound vials for as low as $299 per month on LillyDirect, down from a previous price of $349 per month. They can also access the next dose, 5 milligrams, for $399 per month and all other doses for $449 per month, down from $499 per month across those sizes. 

Zepbound carries a list price of roughly $1,086 per month. That price point, and spotty insurance coverage for weight loss drugs in the U.S., have been significant barriers to access for some patients. 

Eli Lilly’s announcement comes just weeks after President Donald Trump inked deals with Eli Lilly and Novo Nordisk to make their GLP-1 drugs easier for Americans to get and afford. The agreements will cut the prices the government pays for the drugs, introduce Medicare coverage of obesity drugs for the first time for certain patients and offer discounted medicines on the government’s new direct-to-consumer website launching in January, TrumpRx. 

But Eli Lilly’s deal with Trump centers around lowering the prices of a different form of Zepbound – a multi-dose pen – after it wins Food and Drug Administration approval. 

That means Eli Lilly’s Monday announcement around cutting prices on the existing single-dose vials could allow more patients to get discounted treatments more quickly. 

“We will keep working to provide more options — expanding choices for delivery devices and creating new pathways for access — so more people can get the medicines they need,” said Ilya Yuffa, president of Lilly USA and global customer capabilities, in a statement. 

Eli Lilly’s stock, which has climbed more than 36% this year, fell nearly 2% on Monday. Its meteoric rise due to the success of Zepbound and its diabetes injection Mounjaro vaulted it to becoming the first health-care company to hit a $1 trillion market value last month. Though cutting prices means lower revenue per medication sold, Eli Lilly’s sales — and shares — have continued to soar through past pricing announcements as demand balloons.

With single-dose vials, patients need to use a syringe and needle to draw up the medicine and inject it into themselves. Eli Lilly first introduced that form of Zepbound in August 2024. 

It’s unclear how many patients are currently using single-dose vials of Zepbound. But Eli Lilly previously said that direct-to-consumer sales now account for more than a third of new prescriptions of Zepbound. 

Novo Nordisk earlier this month lowered the price of its obesity drug Wegovy and diabetes treatment Ozempic for existing cash-paying patients to $349 per month from $499 per month. That excludes the highest dose of Ozempic. 

The company also launched a temporary introductory offer, which will allow new cash-paying patients to access the two lowest doses of Wegovy and Ozempic for $199 per month for the first two months of treatment. 



Source link

Continue Reading

Business

OBR chairman resigns over Budget leak

Published

on

OBR chairman resigns over Budget leak



The chairman of the Office for Budget Responsibility (OBR) has resigned over the early publication of the watchdog’s forecasts.

Richard Hughes said he was resigning to allow the OBR to “quickly move on from this regrettable incident”.

His resignation follows publication of a report that described the leak as “the worst failure in the 15-year history of the OBR” and strongly criticised the watchdog’s processes for protecting sensitive information.

In a letter to the Chancellor and the chairwoman of the Commons Treasury Committee, Mr Hughes said he took “full responsibility” for “the shortcomings identified in the report”.

He said: “By implementing the recommendations in this report, I am certain the OBR can quickly regain and restore the confidence and esteem that it has earned through 15 years of rigorous, independent economic analysis.”

Mr Hughes has served as chairman of the OBR since 2020 and was reappointed to the job for a second five-year term in July this year.

Speaking in the Commons as the news of the resignation broke, Chief Secretary to the Treasury James Murray offered the Government’s thanks to Mr Hughes “for his dedication to public service”.

Later, the Chancellor herself offered her thanks for Mr Hughes’ “many years of public service”, adding: “This Government is committed to protecting the independence of the OBR and the integrity of our fiscal framework and institutions.”

Conservative leader Kemi Badenoch accused the Chancellor of using Mr Hughes as a “human shield” and called on Rachel Reeves to resign.

Liberal Democrat Treasury spokeswoman Daisy Cooper said Mr Hughes was “a dedicated public servant” who had “rightly taken responsibility for a failure on his watch”, adding the OBR needed to learn from its “catastrophic error”.

Treasury Committee chairwoman Dame Meg Hillier also thanked Mr Hughes, saying: “I commend his decision to take full responsibility for the incident and I wish him well for the future.”

The Treasury said it would begin the process of finding a replacement for Mr Hughes “in the coming weeks”.

The OBR launched an investigation after official forecasts were uploaded to the watchdog’s website, releasing details of the Budget almost an hour early.

In a report published on Monday, the OBR said the leak had been “seriously disruptive to the Chancellor, who had every right to expect that the (forecasts) would not be publicly available until she sat down at the end of her Budget speech”.

Noting Mr Hughes had already “rightly” apologised for the leak, the report said it was “not a case of intentional leakage” or a matter of pressing publish too early.

The OBR said it was caused by two errors linked to the WordPress publishing site it used.

The report into the incident said that, while it knew web addresses for its files follow a pattern, it assumed “the protections provided” by WordPress “would ensure it could not be accessed”.

But two configuration errors were the technical causes of the premature access.

The forecast for the last spring statement in March was also “accessed prematurely” on one occasion, the report noted, but concluded that no activity appeared to have been taken as a result and the most likely explanation is “benign”.

The report recommended a review of the watchdog’s processes for publishing such documents.

“To rebuild trust, the leadership of the OBR must take immediate steps to change completely the publication arrangements for the two important and time-sensitive documents containing the results of its biannual forecasts that it publishes in a normal year, and review arrangements for all other publications,” the report said.

One option would be for the watchdog to use the Government’s digital architecture but publish when it wants.

Another would be to have the Treasury publish the forecasts for the Budget and spring statement, but this would only work if safeguards for “real and perceived independence” could be put in place.

There may need to be an interim solution, the report noted, but said new arrangements must be in place in time for the next statement in spring 2026.



Source link

Continue Reading

Business

OGRA Announces LPG Price Increase for December – SUCH TV

Published

on

OGRA Announces LPG Price Increase for December – SUCH TV



The Oil and Gas Regulatory Authority (OGRA) has approved a fresh increase in the price of liquefied petroleum gas (LPG), raising the cost for both domestic consumers and commercial users.

According to the notification issued, the LPG price has been increased by Rs7.39 per kilogram, setting the new rate at Rs209 per kg for December. As a result, the price of a domestic LPG cylinder has risen by Rs87.21, bringing the new price to Rs2,466.10.

In November, the price of LPG stood at Rs201 per kg, while the domestic cylinder was priced at Rs2,378.89.

The latest price hike is expected to put additional pressure on households already grappling with rising living costs nationwide.



Source link

Continue Reading

Trending